Warts Hand Clinical Trial
Official title:
IL-4 and IFN-γ as Immunologic Predictors of Response to HPV Immunotherapy in Warts
Verified date | November 2023 |
Source | Zagazig University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In the present study the investigators assessed the invitro role of IL-4 and IFN-γ in predicting the response to bivalent HPV vaccine after whole blood stimulation
Status | Completed |
Enrollment | 80 |
Est. completion date | March 2, 2021 |
Est. primary completion date | July 3, 2020 |
Accepts healthy volunteers | |
Gender | All |
Age group | 36 Months and older |
Eligibility | Inclusion Criteria: - Patients with recurrent and recalcitrant cutaneous and anogenital warts. Exclusion Criteria: - History of allergy to the HPV vaccine - Active viral, fungal, or bacterial infections - Immunosuppressive diseases or drugs. - Autoimmune diseases, or other systemic diseases, e.g., hepatic, or renal disorders, diabetes, meningitis or convulsions - Skin allergies - Pregnancy and lactation - Earlier wart treatment at least one month before enrollment. |
Country | Name | City | State |
---|---|---|---|
Egypt | Zagazig University Faculty of Medicine | Zagazig | Sharkia |
Lead Sponsor | Collaborator |
---|---|
Zagazig University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of IFN-? and IL-4 levels | Quantitative measurement of IFN-? and IL-4 in culture supernatants | 48 hours | |
Secondary | Change in the size of warts | Clinical observation and photographing of wart size | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03487549 -
Cantharidin and Occlusion in Verruca Epithelium
|
Phase 2 | |
Completed |
NCT04554394 -
CellFX System for the Treatment of Cutaneous Non-Genital Warts
|
N/A | |
Completed |
NCT04738734 -
CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts
|
N/A |